Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.

Rommerswinkel N, Keil S, Adawy A, Hengstler JG, Niggemann B, Zänker KS, Dittmar T.

Cell Signal. 2018 Dec;52:23-34. doi: 10.1016/j.cellsig.2018.08.016. Epub 2018 Aug 27.

PMID:
30165102
2.

Matrix metalloproteinase-9 (MMP9) is involved in the TNF-α-induced fusion of human M13SV1-Cre breast epithelial cells and human MDA-MB-435-pFDR1 cancer cells.

Weiler J, Mohr M, Zänker KS, Dittmar T.

Cell Commun Signal. 2018 Apr 10;16(1):14. doi: 10.1186/s12964-018-0226-1.

3.

Hybrid clone cells derived from human breast epithelial cells and human breast cancer cells exhibit properties of cancer stem/initiating cells.

Gauck D, Keil S, Niggemann B, Zänker KS, Dittmar T.

BMC Cancer. 2017 Aug 2;17(1):515. doi: 10.1186/s12885-017-3509-9.

4.

Hybrid Cells Derived from Human Breast Cancer Cells and Human Breast Epithelial Cells Exhibit Differential TLR4 and TLR9 Signaling.

Tosun S, Fried S, Niggemann B, Zänker KS, Dittmar T.

Int J Mol Sci. 2016 May 13;17(5). pii: E726. doi: 10.3390/ijms17050726.

5.
6.

Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer.

Stock AM, Klee F, Edlund K, Grinberg M, Hammad S, Marchan R, Cadenas C, Niggemann B, Zänker KS, Rahnenführer J, Schmidt M, Hengstler JG, Entschladen F.

Anticancer Res. 2015 Oct;35(10):5277-85.

PMID:
26408687
7.

Cancer (stem) cell differentiation: An inherent or acquired property?

Mohr M, Zänker KS, Dittmar T.

Med Hypotheses. 2015 Dec;85(6):1012-8. doi: 10.1016/j.mehy.2015.08.017. Epub 2015 Sep 4.

PMID:
26347071
8.

Quantification of cell fusion events human breast cancer cells and breast epithelial cells using a Cre-LoxP-based double fluorescence reporter system.

Mohr M, Tosun S, Arnold WH, Edenhofer F, Zänker KS, Dittmar T.

Cell Mol Life Sci. 2015 Oct;72(19):3769-82. doi: 10.1007/s00018-015-1910-6. Epub 2015 Apr 22.

PMID:
25900663
9.

Analysis of cell migration within a three-dimensional collagen matrix.

Rommerswinkel N, Niggemann B, Keil S, Zänker KS, Dittmar T.

J Vis Exp. 2014 Oct 5;(92):e51963. doi: 10.3791/51963.

10.

Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation.

Stock AM, Hahn SA, Troost G, Niggemann B, Zänker KS, Entschladen F.

Exp Cell Res. 2014 Aug 15;326(2):307-14. doi: 10.1016/j.yexcr.2014.04.022. Epub 2014 May 5.

PMID:
24810090
11.
12.

Virus-specific peptide dependent NK cell cytotoxicity.

Tong L, Assenmacher M, Zänker KS, Jähn P.

Inflamm Allergy Drug Targets. 2014;13(2):128-33.

PMID:
24517290
13.

Fusion of CCL21 non-migratory active breast epithelial and breast cancer cells give rise to CCL21 migratory active tumor hybrid cell lines.

Berndt B, Haverkampf S, Reith G, Keil S, Niggemann B, Zänker KS, Dittmar T.

PLoS One. 2013 May 7;8(5):e63711. doi: 10.1371/journal.pone.0063711. Print 2013.

14.

Norepinephrine inhibits the migratory activity of pancreatic cancer cells.

Stock AM, Powe DG, Hahn SA, Troost G, Niggemann B, Zänker KS, Entschladen F.

Exp Cell Res. 2013 Jul 15;319(12):1744-58. doi: 10.1016/j.yexcr.2013.04.015. Epub 2013 Apr 29.

PMID:
23639786
15.

Targets for anti-metastatic drug development.

Stock AM, Troost G, Niggemann B, Zänker KS, Entschladen F.

Curr Pharm Des. 2013;19(28):5127-34. Review.

PMID:
23607665
16.

Personalized cancer care conference.

Zänker KS, Mihich E, Huber HP, Borresen-Dale AL.

J Pers Med. 2013 Apr 29;3(2):70-81. doi: 10.3390/jpm3020070.

17.

Cell fusion is a potent inducer of aneuploidy and drug resistance in tumor cell/ normal cell hybrids.

Berndt B, Zänker KS, Dittmar T.

Crit Rev Oncog. 2013;18(1-2):97-113. Review.

PMID:
23237554
18.

Novel insights into the role of S100A8/A9 in skin biology.

Kerkhoff C, Voss A, Scholzen TE, Averill MM, Zänker KS, Bornfeldt KE.

Exp Dermatol. 2012 Nov;21(11):822-6. doi: 10.1111/j.1600-0625.2012.01571.x. Epub 2012 Aug 9. Review.

19.

Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugs.

Drell TL 4th, Zanker KS, Entschladen F.

Curr Pharm Des. 2012;18(23):3416-20. Review.

PMID:
22663553
20.

Supplemental Content

Loading ...
Support Center